|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Parkin DM, Piñeros M, Znaor A and Bray F: Cancer statistics for the
year 2020: An overview. Int J Cancer. Apr 5–2021.(Epub ahead of
print). View Article : Google Scholar
|
|
2
|
Travis WD: Lung cancer pathology: Current
concepts. Clin Chest Med. 41:67–85. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bergethon K, Shaw AT, Ou SH, Katayama R,
Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang
R, et al: ROS1 rearrangements define a unique molecular class of
lung cancers. J Clin Oncol. 30:863–870. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
First-line crizotinib versus chemotherapy in ALK-positive lung
cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin JJ, Cardarella S, Lydon CA, Dahlberg
SE, Jackman DM, Jänne PA and Johnson BE: Five-year survival in
EGFR-Mutant metastatic lung adenocarcinoma treated with EGFR-TKIs.
J Thorac Oncol. 11:556–565. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Katoh M and Katoh M: Human FOX gene family
(Review). Int J Oncol. 25:1495–1500. 2004.PubMed/NCBI
|
|
9
|
Zhu H: Forkhead box transcription factors
in embryonic heart development and congenital heart disease. Life
Sci. 144:194–201. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He SY, Shen HW, Xu L, Zhao XH, Yuan L, Niu
G, You ZS and Yao SZ: FOXM1 promotes tumor cell invasion and
correlates with poor prognosis in early-stage cervical cancer.
Gynecol Oncol. 127:601–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiang D, Jiang L, Liu B, Huang H, Li W,
Zhang T, Zu G and Zhang X: Clinicopathological and prognostic
significance of FoxM1 in gastric cancer: A meta-analysis. Int J
Surg. 48:38–44. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kong FF, Qu ZQ, Yuan HH, Wang JY, Zhao M,
Guo YH, Shi J, Gong XD, Zhu YL, Liu F, et al: Overexpression of
FOXM1 is associated with EMT and is a predictor of poor prognosis
in non-small cell lung cancer. Oncol Rep. 31:2660–2668. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim HE, Kim DG, Lee KJ, Son JG, Song MY,
Park YM, Kim JJ, Cho SW, Chi SG, Cheong HS, et al: Frequent
amplification of CENPF, GMNN and CDK13 genes in hepatocellular
carcinomas. PLoS One. 7:e432232012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun J, Huang J, Lan J, Zhou K, Gao Y, Song
Z, Deng Y, Liu L, Dong Y and Liu X: Overexpression of CENPF
correlates with poor prognosis and tumor bone metastasis in breast
cancer. Cancer Cell Int. 19:2642019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ho DW, Lam WM, Chan LK and Ng IO:
Investigation of functional synergism of CENPF and FOXM1 identifies
POLD1 as downstream target in hepatocellular carcinoma. Front Med
(Lausanne). 9:8603952022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Laoukili J, Kooistra MR, Brás A, Kauw J,
Kerkhoven RM, Morrison A, Clevers H and Medema RH: FoxM1 is
required for execution of the mitotic programme and chromosome
stability. Nat Cell Biol. 7:126–136. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Aytes A, Mitrofanova A, Lefebvre C,
Alvarez MJ, Castillo-Martin M, Zheng T, Eastham JA, Gopalan A,
Pienta KJ, Shen MM, et al: Cross-species regulatory network
analysis identifies a synergistic interaction between FOXM1 and
CENPF that drives prostate cancer malignancy. Cancer Cell.
25:638–651. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Langfelder P and Horvath S: WGCNA: An R
package for weighted correlation network analysis. BMC
Bioinformatics. 9:5592008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sato M, Larsen JE, Lee W, Sun H, Shames
DS, Dalvi MP, Ramirez RD, Tang H, DiMaio JM, Gao B, et al: Human
lung epithelial cells progressed to malignancy through specific
oncogenic manipulations. Mol Cancer Res. 11:638–650. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tang H, Xiao G, Behrens C, Schiller J,
Allen J, Chow CW, Suraokar M, Corvalan A, Mao J, White MA, et al: A
12-gene set predicts survival benefits from adjuvant chemotherapy
in non-small cell lung cancer patients. Clin Cancer Res.
19:1577–1586. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Selamat SA, Chung BS, Girard L, Zhang W,
Zhang Y, Campan M, Siegmund KD, Koss MN, Hagen JA, Lam WL, et al:
Genome-scale analysis of DNA methylation in lung adenocarcinoma and
integration with mRNA expression. Genome Res. 22:1197–1211. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res 45 (W1).
W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liberzon A, Subramanian A, Pinchback R,
Thorvaldsdóttir H, Tamayo P and Mesirov JP: Molecular signatures
database (MSigDB) 3.0. Bioinformatics. 27:1739–1740. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Neel DS and Bivona TG: Resistance is
futile: Overcoming resistance to targeted therapies in lung
adenocarcinoma. NPJ Precis Oncol. 1:32017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Clark KL, Halay ED, Lai E and Burley SK:
Co-crystal structure of the HNF-3/fork head DNA-recognition motif
resembles histone H5. Nature. 364:412–420. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang X, Kiyokawa H, Dennewitz MB and Costa
RH: The Forkhead Box m1b transcription factor is essential for
hepatocyte DNA replication and mitosis during mouse liver
regeneration. Proc Natl Acad Sci USA. 99:16881–16886. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kalin TV, Ustiyan V and Kalinichenko VV:
Multiple faces of FoxM1 transcription factor: Lessons from
transgenic mouse models. Cell Cycle. 10:396–405. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Halasi M and Gartel AL: Targeting FOXM1 in
cancer. Biochem Pharmacol. 85:644–652. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Borhani S and Gartel AL: FOXM1: A
potential therapeutic target in human solid cancers. Expert Opin
Ther Targets. 24:205–217. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Varis A, Salmela AL and Kallio MJ: Cenp-F
(mitosin) is more than a mitotic marker. Chromosoma. 115:288–295.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li X, Li Y, Xu A, Zhou D, Zhang B, Qi S,
Chen Z, Wang X, Ou X, Cao B, et al: Apoptosis-induced translocation
of centromere protein F in its corresponding autoantibody
production in hepatocellular carcinoma. Oncoimmunology.
10:19921042021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shahid M, Kim M, Lee MY, Yeon A, You S,
Kim HL and Kim J: Downregulation of CENPF remodels prostate cancer
cells and alters cellular metabolism. Proteomics. 19:e19000382019.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ma Y, Guo J, Li D and Cai X:
Identification of potential key genes and functional role of CENPF
in osteosarcoma using bioinformatics and experimental analysis. Exp
Ther Med. 23:802022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen L, Wu M, Ji C, Yuan M, Liu C and Yin
Q: Silencing transcription factor FOXM1 represses proliferation,
migration, and invasion while inducing apoptosis of liver cancer
stem cells by regulating the expression of ALDH2. IUBMB Life.
72:285–295. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wei P, Zhang N, Wang Y, Li D, Wang L, Sun
X, Shen C, Yang Y, Zhou X and Du X: FOXM1 promotes lung
adenocarcinoma invasion and metastasis by upregulating SNAIL. Int J
Biol Sci. 11:186–198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lin SC, Kao CY, Lee HJ, Creighton CJ,
Ittmann MM, Tsai SJ, Tsai SY and Tsai MJ: Dysregulation of
miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of
prostate cancer. Nat Commun. 7:114182016. View Article : Google Scholar : PubMed/NCBI
|
